Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Falls Church, Virginia Clinical Trials

A listing of Falls Church, Virginia clinical trials actively recruiting patient volunteers.

RESULTS

Found (212) clinical trials

Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer

During the Phase 1 segment, the dose and regimen of MGCD516 will be assessed. During the Phase 1b segment, the clinical activity of MGCD516 will be evaluated in selected patient populations. Patients anticipated to be enrolled in Phase 1b will be selected based upon the following cancer diagnosis: Non-small cell ...

Phase

5.27 miles

Learn More »

A Study of LAM-003 in Patients With Acute Myeloid Leukemia

This clinical trial is a Phase 1 study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of LAM-003 across a range of LAM 003 dose levels when administered to subjects with previously treated relapsed or refractory AML. Subjects will self-administer oral LAM 003 either once or twice per day as ...

Phase

5.27 miles

Learn More »

A Multiple-dose Study of ASP8374 an Immune Checkpoint Inhibitor as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

This is a multi-center, multiple-dose, dose-escalation and expansion study of ASP8374 as a single agent and in combination with pembrolizumab. After discontinuation of study drug treatment, all participants will complete an end of treatment visit and safety follow-up visits. Participants will be enrolled in respectively escalation cohorts or expansion cohorts. ...

Phase

5.27 miles

Learn More »

MGD009/MGA012 Combination in Relapsed/Refractory Cancer

This study is a Phase 1, open-label, dose escalation, and cohort expansion study designed to characterize the safety, tolerability, PK, pharmacodynamics, immunogenicity, and preliminary antitumor activity of the combination of MGD009 and MGA012, each of which is administered by IV infusion.The study consists of a Dose Escalation Phase to determine ...

Phase

5.27 miles

Learn More »

First-in-human Study of DS-1062a for Advanced Solid Tumors

The dosage strength will change during the study but all participants will receive the same study drug. So the study is not a true 2-arm study, it is a 2-part study. In both parts, subjects with pathologically documented unresectable advanced NSCLC who have been refractory to or relapsed from standard ...

Phase

5.27 miles

Learn More »

Study of STRO-001 an Anti-CD74 Antibody Drug Conjugate in Patients With Advanced B-Cell Malignancies

This study is a first-in-human Phase 1, open-label, multicenter, dose escalation study with dose expansion to identify the maximum tolerated dose (MTD), the recommended phase 2 doses (RP2D) and to evaluate the safety, tolerability, and preliminary anti-tumor activity of STRO-001 in adult subjects with B-cell malignancies (MM and NHL) who ...

Phase

5.27 miles

Learn More »

Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC

Pre-clinical studies support the proposed dosing schema to be tested and a potential benefit of the combination of inhaled DV281 with nivolumab for subjects with advanced NSCLC. This study (DV9-NSC-01) is designed for establishing an immunologically optimal RP2D for inhaled DV281 in combination with an approved anti-PD-1 inhibitor. This trial, ...

Phase

5.27 miles

Learn More »

A Study to Evaluate the Effects of Pevonedistat on the Corrected QT (QTc) Interval in Participants With Advanced Solid Tumors

The drug being tested in this study is called pevonedistat. Pevonedistat in combination with standard of care will be used to treat participants who have advanced solid tumors. This study will assess the effects of pevonedistat on the QTc interval in participants with advanced solid tumors. The study will enroll ...

Phase

5.27 miles

Learn More »

A Study of ASP1948 Targeting an Immune Modulatory Receptor in Subjects With Advanced Solid Tumors

This is a dose-escalation and expansion study of ASP1948. The study consists of 3 periods: screening, treatment and follow up, followed by an optional Re-treatment period for participants that qualify. The escalation cohorts will evaluate escalating dose levels of ASP1948 in participants with locally advanced (unresectable) or metastatic solid tumor ...

Phase

5.27 miles

Learn More »

A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer and Gynecologic Malignancies

Dose escalation of the following will be assessed: escalating doses of AB928 in combination with pegylated liposomal doxorubicin (PLD) at standard doses in participants with advanced metastatic triple-negative breast cancer or ovarian cancer; escalating doses of IPI-549 in combination with the recommended phase 2 dose (RP2D) of AB928 and PLD ...

Phase

5.27 miles

Learn More »